Co-mutation in BCL7A further implicates BAF/SWI-SNF dysfunction; in MM, BCL7A loss permits IRF4-driven transcriptional rewiring, providing a rationale to test BAF/EZH2-axis targeting (1). This evidence concerns the gene BANF1 and Miyoshi myopathy.